Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reaching for wellness in schizophrenia.

Deanna L Kelly1, Douglas L Boggs, Robert R Conley

  • 1Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA. dkelly@mprc.umaryland.edu <dkelly@mprc.umaryland.edu>

The Psychiatric Clinics of North America
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.

CNS drugs·2026
Same author

Randomized double-blind inpatient study of a gluten-free diet for negative symptoms in people with schizophrenia.

Schizophrenia research·2026
Same author

Case Report: Metabolic, inflammatory, and neurological improvements after a ketogenic diet in a woman with treatment-resistant schizophrenia and metabolic syndrome.

Frontiers in psychiatry·2025
Same author

Longitudinal analysis of absolute neutrophil count (ANC) variability and neutropenia incidence in African American schizophrenia patients by ACKR1 genotype.

Schizophrenia research·2025
Same author

T cells are associated with negative symptoms in persons with anti-gliadin antibody positive schizophrenia and related disorders.

Schizophrenia research·2025
Same author

Electrochemistry as a Tool for Redox-Based Bio-Information Processing.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

Coronary heart disease (CHD) is a leading cause of death for individuals with schizophrenia. Addressing modifiable risk factors like smoking and hypertension is crucial for improving long-term health outcomes.

Area of Science:

  • Cardiology
  • Psychiatry
  • Public Health

Background:

  • Coronary heart disease (CHD) is a significant cause of mortality in schizophrenia patients.
  • Multiple factors contribute to CHD in this population, including lifestyle, antipsychotic medications, and comorbidities.
  • Certain modifiable risk factors are more prevalent in schizophrenia patients compared to the general population.

Purpose of the Study:

  • To review and highlight the modifiable risk factors for coronary heart disease (CHD) in patients with schizophrenia.
  • To emphasize the increased frequency of these risk factors in individuals with schizophrenia.
  • To advocate for improved management of these risk factors to enhance patient outcomes.

Main Methods:

  • Literature review focusing on modifiable risk factors for CHD in schizophrenia.

Related Experiment Videos

  • Analysis of the prevalence of specific risk factors (smoking, diabetes, hyperlipidemia, hypertension, metabolic syndrome) in schizophrenia patients.
  • Discussion of treatment challenges and recommendations.

    • Main Results:

    • Schizophrenia patients exhibit higher rates of cigarette smoking, diabetes, hyperlipidemia, hypertension, and metabolic syndrome.
    • These factors significantly contribute to the elevated CHD mortality in this population.
    • Current treatment of these risk factors remains suboptimal.

    Conclusions:

    • Managing modifiable risk factors is essential for improving the long-term prognosis of schizophrenia patients.
    • Aggressive management of smoking, diabetes, hypertension, and hyperlipidemia is necessary.
    • Efforts to promote wellness and optimal risk factor control are critical.